Literature DB >> 1626995

IgG antibodies in early Pseudomonas aeruginosa infection in cystic fibrosis.

S M Cordon1, J S Elborn, R J Rayner, E J Hiller, D J Shale.   

Abstract

The relationship between IgG antibodies to Pseudomonas aeruginosa and its isolation from sputum was determined in 100 patients with cystic fibrosis observed at intervals of two months for a median period of one year. Only one patient had a raised antibody titre (greater than 22.9 ELISA units) before isolation of P aeruginosa. Initially 65 patients were antibody negative, of whom 48 were also culture negative. Of 24 patients with positive sputum culture and negative antibodies, seven became antibody positive at a median (range) 15 (6-25) months later. The remaining 17 patients continued antibody negative until the end of the study at a median range 15 (1-123) months after becoming culture positive. This latter group were younger and had more intermittently positive sputum cultures. In general positive IgG antibody titres do not predate isolation of P aeruginosa, but in some patients are present soon after acquisition of infection. A positive titre indicates significant exposure to P aeruginosa and could be used to detect infection in patients unable to produce sputum and possibly indicate the effect of early antipseudomonal treatment.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1626995      PMCID: PMC1793797          DOI: 10.1136/adc.67.6.737

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  9 in total

1.  Serum IgA antibodies against Pseudomonas aeruginosa in cystic fibrosis.

Authors:  M M Brett; A T Ghoneim; J M Littlewood
Journal:  Arch Dis Child       Date:  1990-03       Impact factor: 3.791

2.  Pulmonary function and clinical course in patients with cystic fibrosis after pulmonary colonization with Pseudomonas aeruginosa.

Authors:  E Kerem; M Corey; R Gold; H Levison
Journal:  J Pediatr       Date:  1990-05       Impact factor: 4.406

3.  Artificial urinary sphincters.

Authors:  A R Mundy
Journal:  Arch Dis Child       Date:  1986-01       Impact factor: 3.791

4.  Calculating confidence intervals for some non-parametric analyses.

Authors:  M J Campbell; M J Gardner
Journal:  Br Med J (Clin Res Ed)       Date:  1988-05-21

5.  An ELISA to detect antipseudomonal IgA antibodies in sera of patients with cystic fibrosis.

Authors:  M M Brett; A T Ghoneim; J M Littlewood
Journal:  J Clin Pathol       Date:  1988-10       Impact factor: 3.411

6.  Prevention of chronic Pseudomonas aeruginosa colonisation in cystic fibrosis by early treatment.

Authors:  N H Valerius; C Koch; N Høiby
Journal:  Lancet       Date:  1991-09-21       Impact factor: 79.321

7.  Serum IgG antibodies in patients with cystic fibrosis with early Pseudomonas aeruginosa infection.

Authors:  M M Brett; A T Ghoneim; J M Littlewood
Journal:  Arch Dis Child       Date:  1987-04       Impact factor: 3.791

8.  Treatment of pseudomonas aeruginosa colonisation in cystic fibrosis.

Authors:  G Steinkamp; B Tümmler; R Malottke; H von der Hardt
Journal:  Arch Dis Child       Date:  1989-07       Impact factor: 3.791

9.  Pseudomonas aeruginosa antibodies in blood spots from patients with cystic fibrosis.

Authors:  V Thanasekaraan; M S Wiseman; R J Rayner; E J Hiller; D J Shale
Journal:  Arch Dis Child       Date:  1989-11       Impact factor: 3.791

  9 in total
  5 in total

Review 1.  Microbiology of cystic fibrosis lung infections: themes and issues.

Authors:  J R Govan; J W Nelson
Journal:  J R Soc Med       Date:  1993       Impact factor: 5.344

2.  Serum IgG titres against Pseudomonas aeruginosa.

Authors:  W H Nikolaizik; M H Schöni
Journal:  Arch Dis Child       Date:  1993-03       Impact factor: 3.791

3.  Sera from adult patients with cystic fibrosis contain antibodies to Pseudomonas aeruginosa type III apparatus.

Authors:  J Moss; M E Ehrmantraut; B D Banwart; D W Frank; J T Barbieri
Journal:  Infect Immun       Date:  2001-02       Impact factor: 3.441

4.  Effect of respiratory virus infections including rhinovirus on clinical status in cystic fibrosis.

Authors:  A R Smyth; R L Smyth; C Y Tong; C A Hart; D P Heaf
Journal:  Arch Dis Child       Date:  1995-08       Impact factor: 3.791

5.  Specific decrease of anti-pseudomonal IgA after anti-pseudomonal therapy in cystic fibrosis.

Authors:  K de Boeck; E Eggermont; M Smet; P van Reempts; H P van Bever; W J Stevens
Journal:  Eur J Pediatr       Date:  1995-02       Impact factor: 3.183

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.